You can buy or sell TRVI and other stocks, options, ETFs, and crypto commission-free!
Trevi Therapeutics, Inc. Common Stock, also called Trevi Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. Read More It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
New Haven, Connecticut
52 Week High
52 Week Low
-$0.63 per share